Enliven Therapeutics, Inc. (ELVN)
- Previous Close
16.78 - Open
16.72 - Bid 17.13 x 200
- Ask 17.46 x 200
- Day's Range
16.16 - 17.52 - 52 Week Range
9.80 - 26.00 - Volume
147,785 - Avg. Volume
262,869 - Market Cap (intraday)
804.117M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.01 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
34.33
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
www.enliventherapeutics.comRecent News: ELVN
Performance Overview: ELVN
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ELVN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ELVN
Valuation Measures
Market Cap
804.12M
Enterprise Value
551.30M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.27
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-6.62
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.94%
Return on Equity (ttm)
-44.90%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-71.58M
Diluted EPS (ttm)
-2.01
Balance Sheet and Cash Flow
Total Cash (mrq)
253.15M
Total Debt/Equity (mrq)
0.14%
Levered Free Cash Flow (ttm)
-32.95M